ArticlePloS one2026
Enhanced production of l-fuculose by Escherichia coli engineered via genome-scale metabolic modeling.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
l-Fuculose is a rare deoxyketohexose sugar and is a structural isomer of l-fucose, which exhibits skin-lightening, moisturizing, and anti-aging effects. Due to their structural similarity, l-fuculose is also expected to provide potential health benefits. However, l-fuculose exists only in trace amounts in nature, making extraction from natural sources virtually impossible; to date, it has been synthesized mainly by enzymatic conversion. This approach, however, suffers from major limitations: both the substrate (l-fucose) and the enzyme involved (l-fucose isomerase) are costly; the enzymatic reaction cannot achieve complete conversion due to the chemical equilibrium; and the methods for purification of l-fuculose from the reaction mixture containing both l-fucose and l-fuculose are inefficient and uneconomical. Microbial cell factories have been explored as an alternative route for l-fuculose biosynthesis, but their production titers remain extremely low, limiting their industrial applicability. In this study, a microbial cell factory was engineered in Escherichia coli by redirecting the pathway of l-fucose metabolism toward l-fuculose production. Overexpression of fucA enabled the aldol condensation of lactaldehyde and dihydroxyacetone phosphate to produce l-fuculose-1-phosphate, which was subsequently dephosphorylated to l-fuculose by a sugar phosphatase. To prevent diversion of substrates and products into competing pathways, the fucI, fucK, tpiA, fucO, and aldA genes were deleted. The final engineered strain produced 50.25 ± 4.30 mg/L of l-fuculose, a 32.4-fold increase compared to that achieved previously by microbial biosynthesis. This study establishes a foundation for the industrial production of l-fuculose, which has potential application as a valuable ingredient in cosmetics, functional foods, and pharmaceuticals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.